Salute e Benessere
From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits
Currently, the AI in healthcare sector projected to surpass $110 billion by 2030. However, according to , artificial intelligence could unlock an additional $461 billion in value across healthcare by 2035—on top of a sector already projected to surpass $2.26 trillion .
(OTCQB: AVAI) and joint-venture partner are continuing to raise visibility for their AI-powered diagnostic platform, with CEO Vinicio Vargas recently featured as a speaker at "Macular Spectacular" Ophthalmology Conference in Cartagena, Colombia .
The event brought together leading voices in visual health from across Latin America , with discussions focused on advancing patient outcomes through AI innovation. Vargas, who also sits on the board of , presented Vision AI as a transformative tool to expand access to early diabetic retinopathy screening and reduce preventable blindness throughout the region.
Vargas also highlighted a Q4 2024 alliance with and prepaid‑health‑plan provider Salud 360 that is piloting Vision AI among high‑risk diabetic patients; if successful, the program will be rolled out in the United States, Canada , and Europe through , which holds worldwide rights to technology portfolio .
This momentum builds on a recent regulatory breakthrough in the U.S. market. and recently completed a key pre-submission meeting with the for Vision AI, the companies' flagship diagnostic platform for diabetic retinopathy and other retinal diseases.
"We're truly excited about this next phase," said Vinicio Vargas , CEO at and a member of the Board of Directors of , the company formed by the partnership between and to advance and commercialize technology portfolio. "We're getting ready to begin data collection across primary care clinics in the U.S. with a study that is simple, yet rigorous—comparing our AI-based retinal screening to the readings of three retinologists.
The July 15 meeting marked a critical step toward securing 510(k) clearance for Vision AI. The session offered clear feedback on study design, site selection, and execution strategy—enabling and its clinical trial partner, , to finalize preparations for U.S.-based trials.
"This milestone not only brings us closer to validating our platform in the world's largest healthcare market, but it also paves the way for the upcoming approval of our new automated retinal camera," added Vargas. "We believe will [it] be a game changer—making diabetic retinal screenings faster, more accessible, and available from virtually any point of care."
While regulatory efforts advance in the U.S., the company has already launched a groundbreaking chronic care model across Latin America . The program, now live through and pharmacy chains, offers free, walk-in retinal risk assessments—delivering real-time AI results and connecting at-risk patients directly with clinics and specialists.
Over 30% of diabetics develop diabetic retinopathy, a leading cause of preventable blindness. Vision AI offers early, low-cost screening without the need for an ophthalmologist onsite. The model has gained support from pharmacies, insurers, and pharmaceutical partners—demonstrating real traction across the healthcare value chain.
s role in these efforts continues to grow. Through , which it co-founded and structured, maintains global licensing rights to platform and stands to benefit from both U.S. and international commercialization. The Latin American pilot programs are already generating momentum, with U.S. trials positioned to unlock a vastly larger market.
The company is also preparing a standalone venture to house a potential therapeutic candidate for diabetes—bringing leadership, data, and IP into one streamlined structure for diagnostics and treatment alike.
Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at identifying Alzheimer's, cardiovascular conditions, and other chronic diseases through retinal or blood biomarkers.
A structural simplification may be on the horizon as well. A previously announced non-binding LOI remains active for to acquire 100% of —potentially consolidating all IP, leadership, and commercial rights under one public entity. Such a move would give investors pure-play exposure to this fast-evolving tech stack, while deepening operational alignment between the firms.
(NASDAQ: AGEN) has partnered with AI biotech firm to develop predictive biomarkers for its cancer immunotherapy combo BOT/BAL.
"At , we are committed to transforming cancer care through scientific innovation and next-generation immunotherapies," said Dr. Garo Armen , Chairman and CEO of . "This collaboration with enables us to harness cutting-edge AI to better understand patient biology and tailor treatments more precisely."
By using advanced "virtual cell" models trained on massive tumor datasets, the collaboration aims to identify which patients are most likely to benefit from treatment. This could improve clinical trial outcomes and accelerate personalized cancer care using AI-driven insights
(NASDAQ: CLOV) recently launched a new pharmacy pilot program across New Jersey in partnership with iCare+ network. The initiative enables local pharmacies to use AI tools and real-time data to help seniors manage medications and reduce hospital visits.
"This is more than a new program—it's a new model for how we support our New Jersey members," said Jamie Reynoso, CEO of Medicare Advantage at "By working with the pharmacists who are already embedded in our communities, we can deliver better care, deliver amazing customer experiences and support the independent businesses that keep New Jersey strong."
It's part of strategy to deliver more personal, community-based healthcare while supporting independent pharmacies
(NYSE: ZBH) has entered a definitive agreement to acquire
(NASDAQ: MGRM) for approximately US$177 million in cash, with additional milestone-based payments up to US$12.37 per share.
" technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation," said Ivan Tornos, Chairman, President and CEO of . "Upon closing, our customer-centric portfolio will consist of the most comprehensive and flexible technology ecosystem to support the varying preferences of a vast array of surgeons – now and into the future. With proprietary technology, has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery."
The acquisition adds semi- and fully autonomous orthopedic robotics to ROSA® platform, aiming to create the most comprehensive robotics suite in the orthopedic space. FDA-cleared knee arthroplasty robot is expected to commercialize in 2027, with a fully autonomous version in development.
"Since our inception, we have been singularly focused on advancing orthopedic robotics with technology designed to safely, efficiently and accurately support surgeons with total knee arthroplasty," said Benjamin Sexson , CEO of . "We are thrilled by the opportunity to add our technology to leading portfolio of surgical robotics, navigation solutions and trusted implants and to benefit from their deep industry expertise and global scale."
expects the deal to be accretive by 2028, supporting long-term growth in the high-demand surgical robotics market.
https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Logo - https://mma.prnewswire.com/media/2603685/5425599/USA_News_Group_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/from-diagnosis-to-surgery-how-ai-tech-is-quietly-reshaping-healthcare-profits-302510777.html